|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,244.40 INR | -2.70% |
|
-7.18% | -12.81% |
| Capitalization | 17TCr 185.44Cr 156.7Cr 144.47Cr 136.04Cr 254.09Cr 269.02Cr 1.66TCr 659.19Cr 8.04TCr 695.36Cr 681.04Cr 29TCr | P/E ratio 2026 * |
53.7x | P/E ratio 2027 * | 34.6x |
|---|---|---|---|---|---|
| Enterprise value | 17TCr 184.85Cr 156.21Cr 144.01Cr 135.61Cr 253.29Cr 268.18Cr 1.65TCr 657.11Cr 8.02TCr 693.17Cr 678.89Cr 29TCr | EV / Sales 2026 * |
9.16x | EV / Sales 2027 * | 7.02x |
| Free-Float |
55.75% | Yield 2026 * |
0.12% | Yield 2027 * | 0.11% |
Last Transcript: Neuland Laboratories Limited
| 1 day | -2.70% | ||
| 1 week | -7.18% | ||
| Current month | -12.81% | ||
| 1 month | -15.79% | ||
| 3 months | -18.40% | ||
| 6 months | -5.30% | ||
| Current year | -12.81% |
| 1 week | 12,982.2 |  | 14,050 |
| 1 month | 12,982.2 | | 15,579 |
| Current year | 12,982.2 | | 15,579 |
| 1 year | 10,060 | | 19,748.4 |
| 3 years | 1,323.1 | | 19,748.4 |
| 5 years | 965.85 | | 19,748.4 |
| 10 years | 247.3 | | 19,748.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/12/2015 | |
Abhijit Majumdar
DFI | Director of Finance/CFO | - | 23/11/2022 |
| Chief Tech/Sci/R&D Officer | - | 22/11/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 50 | 01/01/2002 | |
| Chairman | 82 | 07/01/1984 | |
| Director/Board Member | 82 | 20/10/2009 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.70% | -7.18% | -4.51% | +759.58% | 190.67Cr | |
| -2.12% | +3.03% | +41.16% | +207.54% | 97TCr | |
| +0.76% | +0.26% | +51.54% | +30.46% | 53TCr | |
| +0.53% | +1.16% | +29.59% | +46.57% | 39TCr | |
| +0.06% | +0.69% | +27.14% | +18.28% | 38TCr | |
| +0.15% | -3.18% | +23.01% | +21.25% | 28TCr | |
| +0.47% | +1.01% | +28.88% | +36.88% | 28TCr | |
| +1.17% | +9.90% | -30.99% | -16.90% | 28TCr | |
| -0.92% | -2.51% | +13.06% | -1.60% | 27TCr | |
| -0.67% | +4.46% | +26.08% | +30.96% | 19TCr | |
| Average | -0.26% | +1.09% | +20.49% | +113.30% | 35.61TCr | |
| Weighted average by Cap. | -0.09% | +2.10% | +28.98% | +73.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.85TCr 20Cr 17Cr 16Cr 15Cr 28Cr 29Cr 180.62Cr 72Cr 875.33Cr 76Cr 74Cr 3.14TCr | 2.38TCr 26Cr 22Cr 20Cr 19Cr 36Cr 38Cr 232.51Cr 92Cr 1.13TCr 97Cr 95Cr 4.05TCr |
| Net income | 317.4Cr 3.46Cr 2.93Cr 2.7Cr 2.54Cr 4.75Cr 5.03Cr 31Cr 12Cr 150.23Cr 13Cr 13Cr 539.48Cr | 493.03Cr 5.38Cr 4.55Cr 4.19Cr 3.95Cr 7.37Cr 7.81Cr 48Cr 19Cr 233.36Cr 20Cr 20Cr 838.01Cr |
| Net Debt | -54Cr -58.42L -49.37L -45.51L -42.86L -80.05L -84.75L -5.23Cr -2.08Cr -25Cr -2.19Cr -2.15Cr -91Cr | -288.16Cr -3.14Cr -2.66Cr -2.45Cr -2.31Cr -4.31Cr -4.56Cr -28Cr -11Cr -136.39Cr -12Cr -12Cr -489.79Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 13,244.40 ₹ | -2.70% | 1,714 |
| 22/26/22 | 13,611.80 ₹ | +3.37% | 2,449 |
| 21/26/21 | 13,167.85 ₹ | -3.04% | 1,542 |
| 20/26/20 | 13,580.25 ₹ | -2.29% | 2,105 |
| 19/26/19 | 13,899.05 ₹ | -1.21% | 1,066 |
Delayed Quote Bombay S.E., January 23, 2026 at 03:30 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NEULANDLAB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition